STOCK TITAN

Anson Reports 5.23M Shares, Including Warrants, Representing 4.9% of Sellas (SLS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Sellas Life Sciences Group, Inc. (SLS) received a Schedule 13G/A showing that Anson Funds Management LP and related Anson entities and principals collectively report beneficial ownership of 5,225,948 shares, representing 4.9% of the outstanding common stock on a fully diluted basis that includes shares underlying warrants. The reported share count uses 99,777,487 outstanding shares plus 4,950,948 shares issuable upon exercise of warrants to reach a 104,728,435 share denominator. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and that exercise of warrants is subject to beneficial ownership limitations.

Positive

  • Complete disclosure of collective beneficial ownership across related Anson entities and individuals
  • Transparent inclusion of warrants and the denominator used to calculate the 4.9% beneficial ownership
  • Certification that holdings are in the ordinary course of business and not for control purposes

Negative

  • None.

Insights

Anson group holds a sub-5% stake with warrants subject to ownership caps; disclosure suggests passive intent.

The filing documents a collective 4.9% beneficial position in Sellas including warrants, with shared voting and dispositive power across Anson entities and named individuals. Because the position remains below 5%, the filing is made on Schedule 13G/A rather than 13D, consistent with a passive investor stance. The inclusion of warrants and the stated ownership limitation (preventing exercise beyond 4.99% in some warrants) is material for dilution and potential future ownership ceiling analyses.

Filing indicates coordinated group reporting and affirms no intent to influence control; governance impact appears limited.

The named reporting persons—Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., and three individuals—report identical beneficial amounts and shared control over 5,225,948 shares. Signatures from managers and directors certify ordinary-course holding and comparability of non-U.S. regulatory oversight for Anson Advisors Inc. For governance, the sub-5% stake and the certification reduce near-term likelihood of proxy or control actions by this group based on the disclosed facts.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Anson Funds Management LP
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Management GP LLC
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Tony Moore
Signature:/s/ Tony Moore
Name/Title:Tony Moore, Manager
Date:08/14/2025
Anson Advisors Inc.
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025
Amin Nathoo
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo, Director
Date:08/14/2025
Moez Kassam
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam, Director
Date:08/14/2025

FAQ

How many Sellas (SLS) shares do the Anson reporting persons beneficially own?

They report beneficial ownership of 5,225,948 shares, representing 4.9% of the class on a fully diluted basis used in the filing.

Does the Schedule 13G/A indicate Anson intends to influence control of Sellas (SLS)?

No. The filing certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.

Are warrants included in the reported ownership for SLS?

Yes. The calculation includes 4,950,948 shares issuable upon exercise of warrants, and some warrants contain a 4.99% beneficial ownership limitation.

Who are the reporting persons on the SLS Schedule 13G/A?

Reporting persons are Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam.

What voting and dispositive power does Anson report for these SLS shares?

The filing reports 0 sole voting/dispositive power and 5,225,948 shared voting and shared dispositive power.
Sellas Life Sciences Group Inc

NASDAQ:SLS

View SLS Stock Overview

SLS Rankings

SLS Latest News

SLS Latest SEC Filings

SLS Stock Data

914.41M
169.18M
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK